Perrigo Company (PRGO) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
9 Jul, 2026Executive summary
Delivered strong Q1 2025 results with adjusted EPS up 106.9% to $0.60, robust margin expansion, and 19% year-over-year growth in infant formula net sales, supported by cost initiatives and Project Energize savings.
Net sales declined 3.5% year-over-year to $1.04 billion, mainly due to divestitures, currency impacts, and lower sales in Digestive and Women's Health, but organic net sales grew 1.8% excluding lost distribution and prior year Opill/Women's Health stocking.
Advanced the 3S plan (stabilize, streamline, strengthen), with new business awards offsetting prior losses in U.S. store brand OTC and improved service levels to 94%.
Project Energize and supply chain reinvention delivered $8M and $20M in annual savings, with Energize reaching a $159M annual run rate.
International business posted mid-single digit sales growth and double-digit profit growth, now accounting for over 40% of global sales.
Financial highlights
Net sales: $1,043.9 million, down 3.5% year-over-year; organic net sales down 0.4%, but up 1.8% excluding lost distribution and prior year Opill sell-in.
Adjusted gross margin expanded 440 bps to 41.0%; reported gross margin increased 450 bps to 37.6%.
Adjusted operating income rose 57.6% to $147M; reported operating income was $47M, up from a $55M loss prior year.
Adjusted EPS: $0.60 (up 106.9% year-over-year); adjusted net income was $83M, up from $40M.
Cash and cash equivalents at quarter-end: $410M; Q1 operating cash outflow was $65M, mainly due to inventory rebuild, litigation, and restructuring.
Outlook and guidance
Fiscal 2025 reported net sales growth target widened to 0%–3%; organic net sales growth target widened to 1.5%–4.5%, reflecting macro uncertainty and tariff impacts.
Reaffirmed adjusted EPS target of $2.90–$3.10 for 2025 and net leverage target of ~3.5x by year-end.
Expect 2025 earnings phasing to be 40% in H1 and 60% in H2, with significant ramp in infant formula sales in the second half.
Project Energize expected to deliver $140–$170M in annualized pre-tax savings by 2026; supply chain and efficiency programs to provide $200–$300M annual run-rate savings by 2028.
Midterm 2027 targets reaffirmed.
Latest events from Perrigo Company
- Transformation and innovation drive growth and recovery in a resilient global healthcare market.PRGO
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 sales and margins fell, but market share gains and debt reduction support a positive outlook.PRGO
Q2 2026 - Q1 2026 saw lower sales and a $330.8M goodwill impairment, but market share gains and outlook reaffirmed.PRGO
Q1 2026 - Supplement clarifies LTIP share recycling rules for equity awards and voting procedures.PRGO
Proxy filing - Gained OTC market share, delivered cost savings, and targets growth through innovation and efficiency.PRGO
UBS Global Consumer and Retail Conference - Adjusted EPS up 7% to $2.75; FY2026 outlook cautious but expects second-half recovery.PRGO
Q4 2025 - Q3 2025 saw OTC share gains despite sales decline and a downward revision of FY2025 outlook.PRGO
Q3 2025 - Q3 2024 delivered margin expansion, higher adjusted EPS, and infant formula market share gains.PRGO
Q3 2024 - Margin gains and cost savings offset lower sales, supporting reaffirmed 2024 EPS guidance.PRGO
Q2 2024